Argentina Healthcare Industry Regulatory and Reimbursement Landscape Report

2013-04-29
Published : Apr-2013

In 2012, Argentina’s population was 41.5 million, largely due to natural population and immigrants from Europe. The pharmaceutical market was estimated to be worth $5.6 billion, in 2012 and is expected to reach $15 billion by 2020 at a projected Compound Annual Growth Rate (CAGR) of 13.1%. The medical device market was worth approximately $1.7 billion in 2012 and is expected to reach $2.4 billion by 2020 at a CAGR of 4.6%.

 

An essential source of information and analysis on the Argentina’s healthcare, regulatory and reimbursement landscape, this report (http://www.reportsnreports.com/reports/238379-healthcare-regulatory-and-reimbursement-landscape-argentina.html) identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets.

 

 

Scope of the report “Healthcare, Regulatory and Reimbursement Landscape – Argentina” includes:

The report provides information on Argentina’s healthcare, regulatory and reimbursement landscape, including –
– Overview of the pharmaceutical and medical device markets, including size, segmentation, and key drivers and barriers
– Profiles and SWOT analyses of the major players in the pharmaceutical and medical device markets. The key players covered for the pharmaceutical market are Bayer, Novartis, Roche and the key players covered for the medical device market are Medtronic, F. Hoffmann-La Roche, Siemens Healthcare, DePuy and Stryker Corporation
– Insightful review of the reimbursement and regulatory landscape, with details of the reimbursement process, regulatory agencies and market authorization processes for new drug and medical devices
– Detailed analysis of Argentina’s political and economic environment, including economic indicators, demographics, healthcare infrastructure and healthcare expenditure
– An overview of the opportunities for and challenges to growth in the healthcare market

Table of Contents for this report (http://www.reportsnreports.com/reports/238379-healthcare-regulatory-and-reimbursement-landscape-argentina.html) covers:

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 10
2.1 GlobalData Report Guidance 10
3 Overview of Pharmaceutical and Medical Device Market 11
3.1 Pharmaceutical Market 11
3.1.1 Market Overview 11
3.1.2 Supply Channels 14
3.1.3 Market Segments 15
3.1.4 Overview of Major Therapeutic Areas 19
3.1.5 Major Players 27
3.2 Medical Device Market 47
3.2.1 Market Overview 47
3.2.2 Overview of Top Five Segments 49
3.2.3 Diagnostic Market 65
3.2.4 Major Players 67
3.3 Market Drivers and Barriers 89
3.3.1 Drivers 89
3.3.2 Barriers 90
4 Market Access 91
4.1 Reimbursement and Payer Landscape 91
4.1.1 Overview of Healthcare System 91
4.1.2 Reimbursement Process 94
4.1.3 Patient Share in Healthcare Spending 95
4.1.4 Pricing Policies 96
4.2 Regulatory Landscape 96
4.2.1 Overview of Regulatory Agencies 96
4.2.2 Market Authorization Procedure for Pharmaceutical Products 97
4.2.3 New Medical Device Approval Process 98
4.2.4 Exports and Imports 98
4.2.5 Intellectual Property Rights 99
4.2.6 Clinical Trial Regulations 102
4.2.7 Pharmaceutical Advertising Regulations 103
4.2.8 Pharmacy Regulations 103
4.2.9 Prescription by Active Ingredient Name 103
4.2.10 Labeling and Packaging Regulations 104
5 Country Analysis 105
5.1 Political Environment 105
5.1.1 Political Structure 105
5.1.2 Analysis of Current Political Environment 105
5.1.3 Healthcare Policy Initiatives 106
5.2 Economic Landscape 106
5.3 Economic Indicators 107
5.3.1 Gross Domestic Product 107
5.3.2 Gross National Income 110
5.3.3 Inflation 111
5.3.4 Currency Exchange Rate 114
5.3.5 Foreign Direct Investment 115
5.3.6 Foreign Exchange Reserves 116
5.3.7 Trade Balance 117
5.3.8 General Government Structural Balance 119
5.3.9 General Government Gross Debt 120
5.3.10 Major Industries 120
5.4 Demographics 121
5.4.1 Population 121
5.4.2 Education and Literacy 136
5.4.3 Employment 137
5.4.4 Disease Burden 138
5.5 Healthcare Infrastructure 140
5.5.1 Healthcare Facilities 140
5.5.2 Healthcare Parameters 141
5.5.3 Environmental Health 141
5.5.4 Healthcare Personnel 143
5.6 Healthcare Expenditure 144
5.6.1 Overview 144
5.6.2 Share of Public and Private Sector 145
5.7 Trade Associations 146
5.7.1 Argentina Association of Hospital Pharmacists 146
5.7.2 Industrial Chamber of Argentine Pharmaceutical Laboratories 146
5.7.3 Association of Medical Specialties Distributors 146
5.8 Trade Fairs 146
6 Opportunities and Challenges 147
6.1 Opportunities 147
6.2 Challenges 147
7 Appendix 149
7.1 Abbreviations 149
7.2 Bibliography 151
7.3 Methodology 154
7.3.1 Coverage 154
7.3.2 Secondary Research 154
7.3.3 Forecasting 155
7.3.4 Expert Panel Validation 155
7.4 Contact Us 155
7.5 Disclaimer 155

1.1 List of Tables
Table 1: Pharmaceutical Market, Argentina, Revenue, ($bn), 2007–2012 12
Table 2: Pharmaceutical Market, Argentina, Revenue, ($bn), Forecast, 2013–2020 13
Table 3: Drugs Going Off-patent, Revenue ($bn), Global, 2011–2015 15
Table 4: Vaccines Market, Argentina, Revenue, ($m),2007–2012 17
Table 5: Over-the-Counter Drugs Market, Argentina, Revenue, ($m),2007–2012 18
Table 6: Major Therapeutic Areas, Argentina, Revenue, ($m), 2010 19
Table 7: Nervous System Drugs Market, Argentina, Revenue, ($m), 2007–2012 21
Table 8: Cardiovascular Drugs Market, Argentina, Revenue, ($m), 2007–2012 22
Table 9: Gastrointestinal Drugs Market, Argentina, Revenue, ($m), 2007–2012 24
Table 10: Anti-infectives Market, Argentina, Revenue, ($m), 2007–2012 25
Table 11: Anti-cancer Drugs and Immunomodulators Market, Argentina, Revenue, ($m), 2007–2012 26
Table 12: Major Products, Bayer AG, Global, Revenue ($m), 2011 28
Table 13: Late-stage Pipeline, Bayer AG, 2011 29
Table 14: Major Products, Roche, Global, Revenue ($m), 2012 35
Table 15: Late Stage Pipeline, Roche, 2012 36
Table 16: Major Products, Novartis, Global, Revenue ($m), 2012 40
Table 17: Planned Filings, Novartis, 2012 to =2016 41
Table 18: Medical Device Market, Argentina, Revenue, ($bn), 2007–2012 48
Table 19: Medical Device Market, Argentina, Revenue, ($bn), Forecast, 2013–2020 48
Table 20: Medical Device Market, Segments ,Argentina, Revenue ($m), 2012 49
Table 21: Orthopedic Devices Market , Argentina, Revenue, ($m), 2007–2012 50
Table 22: Orthopedic Devices Market , Argentina, Revenue, ($m), Forecast, 2013–2020 51
Table 23: Sales Trends for Major Players*, Orthopedic Devices, Argentina, 2011 52
Table 24: Ophthalmic Devices Market , Argentina, Revenue, ($m), 2007–2012 53
Table 25: Ophthalmic Devices Market , Argentina, Revenue, ($m), Forecast, 2013–2020 54
Table 26: Sales Trends for Major Players*, Ophthalmic Devices, Argentina, 2010 55
Table 27: In Vitro Diagnostics Devices Market , Argentina, Revenue, ($m), 2007–2012 56
Table 28: In Vitro Diagnostics Devices Market , Argentina, Revenue, ($m), Forecast, 2013–2020 57
Table 29: Sales Trends for Major Players*, In Vitro Diagnostics Devices, Argentina, 2010 58
Table 30: Cardiovascular Devices Market , Argentina, Revenue, ($m), 2007–2012 59
Table 31: Cardiovascular Devices Market, Argentina, Revenue, ($m), Forecast, 2013–2020 60
Table 32: Sales Trends for Major Players*, Cardiovascular Devices, Argentina, 2011 61
Table 33: Diabetes Care Devices Market , Argentina, Revenue, ($m), 2007–2012 62
Table 34: Diabetes Care Devices Market , Argentina, Revenue, ($m),Forecast, 2013–2020 63
Table 35: Sales Trends for Major Players*, Diabetes Care Devices, Argentina, 2011 64
Table 36: Diagnostics Market , Argentina, Revenue, ($m), 2007–2012 65
Table 37: Diagnostics Market , Argentina, Revenue, ($m), Forecast, 2013–2020 66
Table 38: Major Medical Device Companies, Argentina, Revenue ($m), 2010 67
Table 39: Major Products, Roche, Revenues ($m), 2012 68
Table 40: Late Stage Pipeline, Roche, 2012 69
Table 41: Major Products, Siemens, Global, Revenue ($m), 2012 72
Table 42: Major Products, Medtronic, Global, Revenue ($m), 2012 75
Table 43: Major Products, Stryker, Global, Revenue ($m), 2010 84
Table 44: Healthcare Spending, Argentina, Out-Of-Pocket Expenditure (%), 2007–2012 95
Table 45: GDP Per Capita ($), Argentina, 2007–2012 107
Table 46: GDP Per Capita ($), Argentina, Forecast, 2013–2020 108
Table 47: GDP, Argentina, Annual Growth (%), 2007–2012 109
Table 48: GNI Per Capita ($), Argentina, 2007–2012 110
Table 49: Average Consumer Price Index, Argentina, 2007–2012 111
Table 50: Average Consumer Price Index, Argentina, 2013–2020 112
Table 51: Average Consumer Price, Argentina, Annual Change (%), 2007–2012 113
Table 52: Currency Exchange Rate ($/ARS), Argentina, 2007–2012 114
Table 53: Foreign Direct Investment ($bn), Argentina, 2007–2012 115
Table 54: Foreign Exchange Reserves ($bn), Argentina, 2007–2012 116
Table 55: Imports of Goods and Services ($bn), Argentina, 2007–2012 117
Table 56: Exports of Goods and Services ($bn), Argentina, 2007–2012 118
Table 57: General Government Structural Balance ($bn), Argentina, 2007–2012 119
Table 58: General Government Gross Debt ($bn), Argentina, 2007–2012 120
Table 59: Population (m), Argentina, 2007–2012 121
Table 60: Population (m), Argentina, Forecast, 2013–2020 122
Table 61: Urban and Rural Population, Argentina, Share (%), 2007–2012 123
Table 62: Urban and Rural Population, Argentina, Share (%), Forecast, 2013–2020 124
Table 63: Age Groups, Argentina, Population Distribution (%), 2007–2012 125
Table 64: Age Groups, Argentina, Population Distribution (%), Forecast, 2013–2020 126
Table 65: Births (Per 1,000 Population), Argentina, 2007–2012 127
Table 66: Mortality (Per 1,000 Population), Argentina, 2007–2012 128
Table 67: Major Causes of Mortality, Argentina, 2009 129
Table 68: Infant Mortality, Argentina, Mortality Rate (Per 1,000 Live Births), 2007–2012 130
Table 69: Immunization Rate for DTP, Measles (%), Argentina, 2007–2012 131
Table 70: Major Causes of Male Mortality, Argentina, 2009 132
Table 71: Major Causes of Female Mortality, Argentina, 2009 133
Table 72: Life Expectancy at Birth (Years), Argentina, 2007–2012 134
Table 73: Life Expectancy at Birth (Years), Argentina, Forecast, 2013–2020 135
Table 74: Students, Argentina, Gross Enrolment (%), 2007–2012 136
Table 75: Unemployment Rate (%), Argentina, 2005–2010 137
Table 76: Reported Cases of Diseases, Argentina, 2010 138
Table 77: Major Diseases, Argentina, DALY (Per 100,000 Population), 2004 139
Table 78: CO2 (‘000 Metric Tons), Argentina, 2007–2012 141
Table 79: PM10 (Micrograms Per Cubic Meter), Argentina, 2007–2012 142
Table 80: Healthcare Expenditure (% of GDP), Argentina, 2007–2012 144
Table 81: Healthcare Expenditure, Argentina, Public–Private Sector (%), 2007–2012 145
Table 82: Major Healthcare Trade Fairs, Argentina, 2012 146

1.2 List of Figures
Figure 1: Pharmaceutical Market, Argentina, Revenue, ($bn), 2007–2012 12
Figure 2: Pharmaceutical Market, Argentina, Revenue, ($bn), Forecast, 2013–2020 13
Figure 3: Pharmaceutical Distribution Channel, Argentina, 2009 14
Figure 4: Vaccines Market, Argentina, Revenue, ($m), 2007–2012 17
Figure 5: Over-the-Counter Drugs Market, Argentina, Revenue, ($m),2007–2012 18
Figure 6: Major Therapeutic Areas, Argentina, Revenue, ($m), 2010 19
Figure 7: Major Therapeutic Areas, Share (% of Total Pharmaceutical Market), Argentina, 2010 20
Figure 8: Nervous System Drugs Market, Argentina, Revenue, ($m), 2007–2012 21
Figure 9: Nervous System Drugs Market ($m), Argentina, 2011 22
Figure 10: Cardiovascular Drugs Market, Argentina, Revenue, ($m), 2007–2012 22
Figure 11: Cardiovascular Drugs Market, Argentina, Revenue, ($m),2011 23
Figure 12: Gastrointestinal Drugs Market, Argentina, Revenue, ($m), 2007–2012 24
Figure 13: Gastrointestinal Drugs Market, Argentina, Revenue, ($m),, 2011 24
Figure 14: Anti-infectives Market, Argentina, Revenue, ($m), 2007–2012 25
Figure 15: Anti-infectives Market ,Argentina, Revenue, ($m), 2011 25
Figure 16: Anti-cancer Drugs and Immunomodulators Market, Argentina, Revenue, ($m), 2007–2012 26
Figure 17: Anti-cancer Drugs and Immunomodulators Market Argentina, Revenue, ($m), 2011 27
Figure 18: Medical Device Market, Argentina, Revenue, ($bn),2007–2012 47
Figure 19: Medical Device Market, Argentina, Revenue, ($bn), Forecast, 2013–2020 48
Figure 20: Medical Device Market,Segments Argentina, Revenue ($m), 2012 49
Figure 21: Orthopedic Devices Market, Argentina, Revenue, ($m), 2007–2012 50
Figure 22: Orthopedic Devices Market , Argentina, Revenue, ($m), Forecast, 2013–2020 51
Figure 23: Sales Trends for Major Players*, Orthopedic Devices, Argentina, 2006–2011 52
Figure 24: Ophthalmic Devices Market , Argentina, Revenue, ($m), 2007–2012 53
Figure 25: Ophthalmic Devices Market , Argentina, Revenue, ($m), Forecast, 2013–2020 54
Figure 26: Sales Trends for Major Players*, Ophthalmic Devices, Argentina, 2006–2010 55
Figure 27: In Vitro Diagnostics Devices Market , Argentina, Revenue, ($m), 2007–2012 56
Figure 28: In Vitro Diagnostics Devices Market , Argentina, Revenue, ($m), Forecast, 2013–2020 57
Figure 29: Sales Trends for Major Players*, In Vitro Diagnostics Devices, Argentina, 2006–2010 58
Figure 30: Cardiovascular Devices Market , Argentina, Revenue, ($m), 2007–2012 59
Figure 31: Cardiovascular Devices Market , Argentina, Revenue, ($m), Forecast, 2013–2020 60
Figure 32: Sales Trends for Major Players*, Cardiovascular Devices, Argentina, 2006–2011 61
Figure 33: Diabetes Care Devices Market , Argentina, Revenue, ($m), 2007–2012 62
Figure 34: Diabetes Care Devices Market , Argentina, Revenue, ($m), Forecast, 2013–2020 63
Figure 35: Sales Trends for Major Players*, Diabetes Care Devices, Argentina, 2006–2011 64
Figure 36: Diagnostics Market , Argentina, Revenue, ($m), 2007–2012 65
Figure 37: Diagnostics Market , Argentina, Revenue, ($m), Forecast, 2013–2020 66
Figure 38: Major Medical Device Companies, Argentina, Revenue ($m), 2010 67
Figure 39: Drivers and Barriers, Healthcare Market, Argentina, 2012 90
Figure 40: Healthcare System Financing and Provisions, Argentina 93
Figure 41: Drug Reimbursement Scenarios, Argentina, 2009–2010 94
Figure 42: Healthcare Spending, Argentina, Out-Of-Pocket Expenditure (%), 2007–2012 95
Figure 43: Healthcare Administration, Argentina, 2012 97
Figure 44: GDP Per Capita ($), Argentina, 2007–2012 107
Figure 45: GDP Per Capita ($), Argentina, Forecast, 2013–2020 108
Figure 46: GDP, Argentina, Annual Growth (%), 2007–2012 109
Figure 47: GNI Per Capita ($), Argentina, 2007-2012 110
Figure 48: Average Consumer Price Index, Argentina, 2007–2012 111
Figure 49: Average Consumer Price Index, Argentina, Forecast 2013–2020 112
Figure 50: Average Consumer Price, Argentina, Annual Change (%), 2007–2012 113
Figure 51: Currency Exchange Rate ($/ARS), Argentina, 2007–2012 114
Figure 52: Foreign Direct Investment ($bn), Argentina, 2007–2012 115
Figure 53: Foreign Exchange Reserves ($bn), Argentina, 2007–2012 116
Figure 54: Imports of Goods and Services ($bn), Argentina, 2007–2012 117
Figure 55: Exports of Goods and Services ($bn), Argentina, 2007–2012 118
Figure 56: General Government Structural Balance ($bn), Argentina, 2007–2012 119
Figure 57: General Government Gross Debt ($bn), Argentina, 2007–2012 120
Figure 58: Population (m), Argentina, 2007–2012 121
Figure 59: Population (m), Argentina, Forecast, 2013–2020 122
Figure 60: Urban and Rural Population, Argentina, Share (%), 2007–2012 123
Figure 61: Urban and Rural Population, Argentina, Share (%), Forecast, 2013–2020 124
Figure 62: Age Groups, Argentina, Population Distribution (%), 2007–2012 125
Figure 63: Age Groups, Argentina, Population Distribution (%), Forecast, 2013–2020 126
Figure 64: Births (Per 1,000 Population), Argentina, 2007–2012 127
Figure 65: Mortality (Per 1,000 Population), Argentina, 2007–2012 128
Figure 66: Major Causes of Mortality, Argentina, 2009 129
Figure 67: Infant Mortality, Argentina, Mortality Rate (Per 1,000 Live Births), 2007–2012 130
Figure 68: Immunization Rate for DTP, Measles (%), Argentina, 2007–2012 131
Figure 69: Major Causes of Male Mortality, Argentina, 2009 132
Figure 70: Major Causes of Female Mortality, Argentina, 2009 133
Figure 71: Life Expectancy at Birth (Years), Argentina, 2007–2012 134
Figure 72: Life Expectancy at Birth (Years), Argentina, Forecast, 2013–2020 135
Figure 73: Students, Argentina, Gross Enrolment (%), 2007–2012 136
Figure 74: Unemployment Rate (%), Argentina, 2005–2010 137
Figure 75: Reported Cases of Diseases, Argentina, 2010 138
Figure 76: Major Diseases, Argentina, DALY (Per 100,000 Population), 2004 139
Figure 77: Number of Out-patient Care Facilities, Argentina, 2010 140
Figure 78: CO2 (‘000 Metric Tons), Argentina, 2007–2012 141
Figure 79: PM10 (Micrograms Per Cubic Meter), Argentina, 2007–2012 142
Figure 80: Healthcare Expenditure (% of GDP), Argentina, 2007–2012 144
Figure 81: Healthcare Expenditure, Argentina, Public–Private Sector (%), 2007–2012 145
Figure 82: Opportunities and Challenges, Healthcare Market, Argentina, 2012 148

Contact [email protected] for further information.

Filed in: Pharmaceuticals and Healthcare
Tags: 
More Reports
Title Price Buy Now

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

“The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......
 $4950

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases,  growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders,  rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on  product in 2021.” Based on products, the topical drug delivery the market is segmented into ......
 $4950

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

“Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......
 $4950

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027

The global Healthcare cloud computing market is projected to reach USD 89.4  billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......
 $4950

Digital Pathology Market by Product (ArtificiaI Intelligence, Scanner, Software, Storage), Type (Human, Veterinary), Application (Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma, Academia, Hospitals) – Global Forecast to 2026

“The Digital Pathology market is projected to grow at a CAGR of 13.2% during the forecast period (2021–2026).” The global digital pathology market is projected to reach USD 1,371 million by 2026 from USD 736 million in 2021, at a CAGR of 13.2% during the forecast period. The growth in the digital pathology market is mainly driven by factors such as the increasing adoption of digital pathology to enhance lab efficiency, rising incidence of cancer, and growing applications of digital pathology in drug development and companion diagnostics. On the other hand, the high costs of digital pathology systems are expected to restrain market growth to a certain extent. “The scanners segment accounted for the largest share of the Digital Pathology market in 2020.” Based on products,......
 $4950

Telehealth & Telemedicine Market by Component (Software & Services (RPM, Real-Time), Hardware (Monitors)), Delivery (On-Premise, Cloud-Based), Application (Teleradiology, Telestroke, TeleICU), End User (Provider, Payer) & Region – Global Forecasts to 2027

“The telehealth & telemedicine market is projected to grow at a CAGR of 26.6% during the forecast period (2022–2027).” The global telehealth & telemedicine market is expected to grow at a CAGR of 26.6% during the forecast period, to reach USD 285.7 billion by 2027 from an estimated USD 87.8 billion in 2022.The key factors driving the growth of this market include the need to expand healthcare access, the growing prevalence of chronic diseases and conditions, a shortage of physicians, advancements in telecommunications, government support and raising awareness, and rising technology adoption in the wake of COVID-19. However, regional variations in regulations, fraud, and the use of social media for care providers will restrict the market growth during the forecast period. ......
 $4950

Teleradiology Market by Product & Service (Services, Hardware, Software (PACS, RIS)), Imaging Technique (MRI, CT, X-ray, Ultrasound, Mammography, Nuclear Imaging), End User (Hospitals, Diagnostic Centers& Laboratories), COVID-19 Impact – Forecast to 2026

“A shortage of skilled radiologists & need for faster and improved diagnosis are driving market growth” The teleradiology market is expected to reach USD 14.8billion by 2026 from USD 7.3 billion in 2021, at a CAGR of 15.3% during the forecast period of 2021 to 2026. Due to the outbreak of coronavirus globally, there is a sudden rise in the demand for teleradiology services. The growth of this market is mainly attributed to the growth of the teleradiology market is driven by the rising geriatric population and the subsequent increase in the prevalence of associated diseases; the increasing number of advanced imaging procedures and a shortage of skilled radiologists; advancements in teleradiology the increasing adoption of cloud-based solutions. However, declining reimbursements a......
 $4950

Healthcare Consulting Services Market by Type of Service (Digital Health, IT, Operations, Strategy, Financial, HR & Talent), End User (Government Bodies, Healthcare Providers, Pharmaceutical & Biotechnology Companies), and Region – Global Forecasts to 2026

Global healthcare consulting services market is projected to grow at CAGR of 11.5%” The global healthcare consulting services market is projected to reach USD 41.2 billion by 2026 from USD 23.9 billion in 2021, at a CAGR of 11.5% during the forecast period. Healthcare consulting firms specialize in providing business consulting services to the healthcare industry in areas such as finance, accounting, marketing, insurance, healthcare management, billing, coding, regulations & compliance, healthcare standards, and many other similar areas. Growth in the healthcare consulting services market can be primarily attributed to the growing budget cuts, increasing pricing pressure, changing healthcare policies/regulations, and rising technological disruption across the healthcare industry t......
 $4950

Animal Growth Promoters and Performance Enhancers Market by Type (Antibiotic and Non-antibiotic (Hormones, Acidifiers, Feed Enzymes, Probiotics & Prebiotics, Phytogenic)), Animal Type (Poultry, Porcine, Livestock, Aquaculture) – Global Forecast to 2026

“The global animal growth promoters and performance enhancers market is projected to grow at a CAGR of 5.7%” The global animal growth promoters and performance enhancers market is projected to reach USD 21.4 billion by 2026 from USD 16.2 billion in 2021, at a CAGR of 5.7%. Animal health products, including growth promoters and performance enhancers, are types of drugs and chemicals used for animal growth. These enhancers help to digest food more effectively and enable animals to grow faster, which, in turn, help to improve productivity. Growth in the animal growth promoters and performance enhancers market is majorly driven by the rising demand for animal consumption and consumption of livestock-based products, rising global demand for naturally produced growth promoters, and rising......
 $4950

Hemophilia A and B – Epidemiology Forecast to 2030

Hemophilia A and B - Epidemiology Forecast to 2030 Summary Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation because of deficiencies in the production or function of coagulation factor VIII in hemophilia A or factor IX in hemophilia B (Bolton-Maggs and Pasi, 2003). Because of the deficiency of coagulation factor, hemophilia patients have a tendency to bleed in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease (CDC, 2021; Mayo Clinic, 2021). According to the World Federation of Hemophilia (WFH), hemophilia is rare. About 1 in 10,000 people are born with hemophilia A and about 1 in 50,000 people are born with hemophilia B......
 $3995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy